35090-76-7

Upstream product

• 5034-74-2 5-bromo-3-methoxysalicylaldehyde 
• 877-22-5 3-methoxysalicylic acid 

Downstream Products

• 100245-46-3 5-Bromo-2-hydroxy-3-methoxy-N-(1H-tetrazol-5-yl)-benzamide 
• 128600-22-6 (-)-(S)-5-bromo-N-<(1-ethyl-2-pyrrolidinyl)methyl>-2-hydroxy-3-methoxybenzamide 
• 134419-43-5 5-bromo-2-hydroxy-3-methoxy-benzoic acid methyl ester 
• 72517-15-8 2,3-dihydroxy-5-bromobenzoic acid 
• 1045810-34-1 (S)-5-bromo-N-[(1-cyclopropylmethyl-2-pyrrolidinyl)methyl]-2-hydroxy-3-methoxybenzamide 
• 1269797-10-5 5-bromo-2-(2-fluoroethoxy)-3-methoxybenzoic acid 
• 1315562-25-4 C₁₁H₁₂BrFO₄ 
• 1269797-41-2 5-bromo-2-(2-fluoroethoxy)-3-methoxy-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)-trans-butyl-2-enyl)benzamide 

Relevant academic research and scientific papers

Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein

Compounds that are dual aP2/k-FABP inhibitors are provided having the formula wherein A, B, X, Y, R1, R2 and R3 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing dual aP2/k-FABP inhibitors alone or in combination with at least one other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.